MA32819B1 - Vaccin combine notamment contre la coqueluche acellulaire - Google Patents

Vaccin combine notamment contre la coqueluche acellulaire

Info

Publication number
MA32819B1
MA32819B1 MA33875A MA33875A MA32819B1 MA 32819 B1 MA32819 B1 MA 32819B1 MA 33875 A MA33875 A MA 33875A MA 33875 A MA33875 A MA 33875A MA 32819 B1 MA32819 B1 MA 32819B1
Authority
MA
Morocco
Prior art keywords
vaccine
combinally
acellular
poultry
relates
Prior art date
Application number
MA33875A
Other languages
Arabic (ar)
English (en)
Inventor
Rajesh Jain
Sukhjeet Singh
Lavit Jambu
Original Assignee
Panacea Biotec Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Panacea Biotec Ltd filed Critical Panacea Biotec Ltd
Publication of MA32819B1 publication Critical patent/MA32819B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN VACCIN COMBINÉ COMPRENANT UN MÉLANGE D'ANTIGÈNES POUR LA PROTECTION CONTRE DES MALADIES TELLES QUE LA DIPHTÉRIE, LE TÉTANOS, LA COQUELUCHE ACELLULAIRE, DES INFECTIONS PAR HAEMOPHILUS INFLUENZAE ET DES VIRUS DE LA POLIO. LA PRÉSENTE INVENTION CONCERNE AUSSI L'INCLUSION D'UN OU DE PLUSIEURS ANTIGÈNES POUR LA PROTECTION CONTRE DES INFECTIONS PAR, LE VIRUS DE L'HÉPATITE, ET D'AUTRES PATHOGÈNES, DE SORTE QUE L'ADMINISTRATION DE CE VACCIN PUISSE SIMULTANÉMENT IMMUNISER UN SUJET CONTRE PLUS D'UN PATHOGÈNE. CETTE INVENTION EN PARTICULIER CONCERNE UN VACCIN COMBINÉ STABLE, COMPLÈTEMENT LIQUIDE, COMPRENANT LES ANTIGÈNES TELS QUE SUSMENTIONNÉS ET LES PROCÉDÉS DE FABRICATION DE CE VACCIN.
MA33875A 2008-10-24 2011-05-20 Vaccin combine notamment contre la coqueluche acellulaire MA32819B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2438DE2008 2008-10-24
PCT/IN2009/000600 WO2010046935A1 (fr) 2008-10-24 2009-10-23 Vaccin combiné notamment contre la coqueluche acellulaire

Publications (1)

Publication Number Publication Date
MA32819B1 true MA32819B1 (fr) 2011-11-01

Family

ID=42119003

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33875A MA32819B1 (fr) 2008-10-24 2011-05-20 Vaccin combine notamment contre la coqueluche acellulaire

Country Status (14)

Country Link
US (1) US8551451B2 (fr)
EP (2) EP2362781A4 (fr)
JP (1) JP2012506421A (fr)
CN (1) CN102196818A (fr)
AP (1) AP2011005701A0 (fr)
AR (1) AR073959A1 (fr)
BR (1) BRPI0920630A2 (fr)
CA (1) CA2741396A1 (fr)
CL (1) CL2011000914A1 (fr)
CO (1) CO6430434A2 (fr)
MA (1) MA32819B1 (fr)
PE (1) PE20100366A1 (fr)
RU (2) RU2526214C2 (fr)
WO (1) WO2010046935A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2491947A3 (fr) 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccin
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
CN103442730B (zh) * 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
FR2992656B1 (fr) * 2012-07-02 2016-10-07 Sanofi Pasteur Procede de production d'antigenes haemophilus influenzae type b
PT2884996T (pt) * 2012-08-17 2020-02-21 Intervet Int Bv Uma composição imunogénica de bactérias de leptospira mortas
EP2863943B1 (fr) * 2013-03-08 2016-07-13 Crucell Holland B.V. Vaccin anticoquelucheux acellulaire
US9849066B2 (en) 2013-04-24 2017-12-26 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
KR20160040290A (ko) * 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
CN105861535B (zh) * 2015-01-20 2019-10-25 中国人民解放军军事医学科学院生物工程研究所 伤寒糖蛋白的生物制备方法及其应用
CN106075428A (zh) * 2015-07-01 2016-11-09 北京科兴中维生物技术有限公司 一种免疫原性组合物及其制备方法
KR102657910B1 (ko) * 2017-07-18 2024-04-18 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 개선된 안정성, 강화된 면역원성과 감소된 반응원성을 갖는 면역원성 조성물 및 그의 제조 방법
CN109550046B (zh) * 2018-12-21 2020-08-25 北京民海生物科技有限公司 一种吸附无细胞百白破-脊髓灰质炎-b型流感嗜血杆菌联合疫苗及其制备方法
WO2020165920A1 (fr) * 2019-02-12 2020-08-20 Biological E Limited Composition vaccinale multivalente
CN110917344B (zh) * 2019-12-26 2022-11-04 北京科兴中维生物技术有限公司 一种液体疫苗组合物及其应用
CN111053898B (zh) * 2019-12-26 2023-05-16 北京科兴中维生物技术有限公司 一种疫苗组合物及其应用
WO2021176409A1 (fr) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Combinaison de conservateurs pour composition de vaccin
US20240238298A1 (en) * 2021-05-26 2024-07-18 Emory University JAK Inhibitors for Managing Conditions in Patients with Down's Syndrome or Other Trisomy
WO2025109417A1 (fr) * 2023-11-21 2025-05-30 Panacea Biotec Limited Composition immunogène d'haemophilus influenzae conjuguée à la protéine d
CN119548620B (zh) * 2025-01-23 2025-09-12 康希诺生物股份公司 一种用于预防白喉、百日咳和破伤风的免疫原性组合物、疫苗及其制备方法和应用
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3626996B2 (ja) * 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20020054884A1 (en) * 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
BR9710460A (pt) 1996-07-02 1999-08-17 Connaught Lab Composi-Æo imunolÄgica multi-valente e seu uso em vacinas
AU4707097A (en) 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0405787D0 (en) * 2004-03-15 2004-04-21 Chiron Srl Low dose vaccines
CA2621023C (fr) 2005-09-01 2019-07-02 Novartis Vaccines And Diagnostics Gmbh & Co. Kg Vaccination multiple comprenant des meningocoques du serogroupe c
US20070065462A1 (en) * 2005-09-21 2007-03-22 Ryall Robert P Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture

Also Published As

Publication number Publication date
EP2362781A4 (fr) 2012-12-05
EP2362781A1 (fr) 2011-09-07
CO6430434A2 (es) 2012-04-30
US8551451B2 (en) 2013-10-08
CN102196818A (zh) 2011-09-21
WO2010046935A1 (fr) 2010-04-29
AP2011005701A0 (en) 2011-06-30
RU2526214C2 (ru) 2014-08-20
AR073959A1 (es) 2010-12-15
CL2011000914A1 (es) 2012-01-20
RU2013101418A (ru) 2014-07-20
PE20100366A1 (es) 2010-05-21
US20110206726A1 (en) 2011-08-25
JP2012506421A (ja) 2012-03-15
RU2011120308A (ru) 2012-11-27
EP2529749A1 (fr) 2012-12-05
BRPI0920630A2 (pt) 2016-01-12
CA2741396A1 (fr) 2010-04-29
RU2634393C2 (ru) 2017-10-26

Similar Documents

Publication Publication Date Title
MA32819B1 (fr) Vaccin combine notamment contre la coqueluche acellulaire
WO2008112344A3 (fr) Matériaux de matrice extracellulaires comme adjuvants de vaccin pour maladies associées à des toxines ou à des pathogènes infectieux
MX2009001412A (es) Vacunas de matriz de proteinas y metodos de hacer y administrar tales vacunas.
PH12019500289A1 (en) Vaccines directed against a human enteroviruses
MX2009006760A (es) Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedades meningococicas.
GB201101665D0 (en) Immunogenic compositions
AR086078A1 (es) Proteinas de fusion y vacunas de combinacion
GEP201706766B (en) Methods and compositions for vaccinating against staphylococcus aureus
EA201391456A1 (ru) ВАКЦИНА ПРОТИВ Streptococcus pneumoniae
RU2014127714A (ru) ВАКЦИНА НА ОСНОВЕ ТОКСИНОВ Clostridium difficile
WO2009009759A3 (fr) Antigènes yersinia pestis, compositions de vaccins, et méthodes associées
CO6430435A2 (es) Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas
WO2008134643A3 (fr) Antigènes de trypanosome, compositions de vaccins et procédés associés
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
EA201690115A1 (ru) Комбинированные иммуногенные композиции
BR112013001168A2 (pt) "toxóide, composição farmacêutica, método de produzir uma antitoxina, antitoxina, e, métodos de tratar um indivíduo intoxicado de vacinação contra a intoxicação por uma toxina e de tratar um mamífero intoxicado."
WO2011112906A3 (fr) Nouveaux immunogènes et procédés pour la découverte et le dépistage de ceux-ci
MX2012004448A (es) Clones infecciosos de torque teno virus.
WO2013171661A3 (fr) Formulations d'adjuvant et méthodes associées
MX2009011312A (es) Regimen de vacunacion para vacunas de celulas b.
MX2009004922A (es) Cultivo in vitro de especies helicobacter.
NZ591738A (en) Non-typhoidal salmonella vaccines comprising a polypeptide which is an outer membrane protein d of non typoidal salmonella
WO2009005917A3 (fr) Procédés de traitement de la maladie infectieuse de la rougeole chez les mammifères
EP2061506A4 (fr) Composition vaccinale et méthode d'immunisation
WO2005117956A3 (fr) Vaccin